research paper
Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial